Breaking news: CDC announces shortage of antimalarial drug primaquine
The Centers for Disease Control and Prevention warned this week that the antimalarial drug primaquine is not available until September, 2011.
The Centers for Disease Control and Prevention (CDC) warned this week that the antimalarial drug primaquine is not available until September, 2011.
Primaquine’s manufacturer, Sanofi-Aventis, reported the drug shortage to the CDC. Sanofi-Aventis representatives did not respond to Formulary’s request for comment.
“Primaquine is the only drug that can be used to eliminate hypnozoites, the dormant forms of malaria parasites,” the CDC said in a statement. Still, healthcare providers may choose to maintain persons at risk of relapse on weekly chloroquine prophylaxis until primaquine is available again.
“Additionally, during the shortage, primaquine should not be prescribed for primary chemoprophylaxis,” the CDC stated.
Besides primaquine and chloroquine, medications recommended to treat malaria include atovaquone/proguanil, doxyclycline, and mefloquine.
Nearly 82 million malaria cases were reported worldwide in 2009, with the highest prevalence in Uganda, Kenya, and the Democratic Republic of Congo.
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
Trelegy and Breo Offer Incremental Improvement Over Generics
March 3rd 2025The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat patients with chronic obstructive pulmonary disease that are part of CMS's drug price negotiation program.
Read More
